High Expression of JMJD4 Is a Potential Diagnostic and Prognostic Marker of Renal Cell Carcinoma

Table 2

Correlation between the expression of JMJD4 and clinical characteristics.

Characteristic	Low expression of JMJD4	High expression of JMJD4
	269	270
T stage, (%)			0.369
T1	147 (27.3%)	131 (24.3%)
T2	37 (6.9%)	34 (6.3%)
T3	80 (14.8%)	99 (18.4%)
T4	5 (0.9%)	6 (1.1%)
N stage, (%)			0.224
N0	136 (52.9%)	105 (40.9%)
N1	6 (2.3%)	10 (3.9%)
M stage, (%)			0.016
M0	231 (45.7%)	197 (38.9%)
M1	30 (5.9%)	48 (9.5%)
Pathologic stage, (%)			0.083
Stage I	144 (26.9%)	128 (23.9%)
Stage II	34 (6.3%)	25 (4.7%)
Stage III	58 (10.8%)	65 (12.1%)
Stage IV	32 (6%)	50 (9.3%)
Primary therapy outcome, (%)			0.762
PD	4 (2.7%)	7 (4.8%)
SD	4 (2.7%)	2 (1.4%)
PR	1 (0.7%)	1 (0.7%)
CR	63 (42.9%)	65 (44.2%)
Gender, (%)			0.003
Female	76 (14.1%)	110 (20.4%)
Male	193 (35.8%)	160 (29.7%)
Race, (%)			0.091
Asian	5 (0.9%)	3 (0.6%)
Black or African American	21 (3.9%)	36 (6.8%)
White	240 (45.1%)	227 (42.7%)
Age, (%)			0.111
≤60	144 (26.7%)	125 (23.2%)
>60	125 (23.2%)	145 (26.9%)
Histologic grade, (%)			0.073
G1	6 (1.1%)	8 (1.5%)
G2	124 (23.4%)	111 (20.9%)
G3	106 (20%)	101 (19%)
G4	27 (5.1%)	48 (9%)
OS event, (%)			0.018
Alive	196 (36.4%)	170 (31.5%)
Dead	73 (13.5%)	100 (18.6%)
DSS event, (%)			0.007
Alive	223 (42.2%)	197 (37.3%)
Dead	41 (7.8%)	67 (12.7%)
PFI event, (%)			0.041
Alive	200 (37.1%)	178 (33%)
Dead	69 (12.8%)	92 (17.1%)
Age,			0.145